Mesothelin-targeted agents in clinical trials and in preclinical development

Ronan J. Kelly, Elad Sharon, Ira Pastan, Raffit Hassan

Research output: Contribution to journalReview articlepeer-review

Abstract

Mesothelin is a tumor differentiation antigen that is highly expressed in several malignant diseases in humans, including malignant mesothelioma and pancreatic, ovarian, and lung adenocarcinomas. The limited expression of mesothelin on normal human tissues and its high expression in many common cancers make it an attractive candidate for cancer therapy. Several agents, including an immunotoxin, monoclonal antibody, antibody drug conjugate, and tumor vaccine, are in various stages of development to treat patients with mesothelin-expressing tumors. This review highlights ongoing clinical trials, as well as other approaches to exploit mesothelin for cancer therapy, that are in preclinical development.

Original languageEnglish (US)
Pages (from-to)517-525
Number of pages9
JournalMolecular cancer therapeutics
Volume11
Issue number3
DOIs
StatePublished - Mar 2012

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Mesothelin-targeted agents in clinical trials and in preclinical development'. Together they form a unique fingerprint.

Cite this